OrbiMed Advisors Reports 1% Decrease in Adicet Bio (ACET) Stake to 8.8% Following Series of Share Sales

OrbiMed Advisors LLC and its affiliated entities filed Amendment No. 9 to their Schedule 13D for Adicet Bio, Inc. (ACET) on April 10, 2026. The filing reports a significant decrease in beneficial ownership, with the Reporting Persons' aggregate holdings dropping by more than 1% since the previous amendment. Specifically, between April 7 and April 9, 2026, several OrbiMed-affiliated funds (OIP, OIP II, and Genesis) sold a combined total of 183,158 shares at prices ranging from $6.29 to $6.80 per share. Following these transactions, OrbiMed Genesis Master Fund, OrbiMed Israel Partners, and OrbiMed Israel Partners II now hold zero shares. The remaining holdings are concentrated in OrbiMed Private Investments V, LP (564,147 shares) and OrbiMed Private Investments VI, LP (280,640 shares). Collectively, OrbiMed Advisors LLC maintains beneficial ownership of 844,787 shares, representing approximately 8.8% of the issuer's outstanding common stock based on 9,596,407 shares outstanding as of March 12, 2026. The reporting persons intend to review their investment on an ongoing basis and may acquire or dispose of further shares based on market conditions.